



UNIVERZITET U NOVOM SADU
MEDICINSKI FAKULTET



Nacionalni simpozijum sa međunarodnim učešćem
„4. DAN VAKCINACIJE“
6-7. novembar 2024. godine
Hotel Sheraton, Novi Sad

Imunizacija odraslih protiv RSV


Miloš Marković

Institut za mikrobiologiju i imunologiju
Medicinski fakultet Univerziteta u Beogradu

Zašto je važno da se odrasli vakcinišu protiv RSV?

RSV infekcija pogađa odrasle, ali se bolest često ne prepoznaje

Klinički tok infekcije RSV u odnosu na životnu dob




- An exceptional mucosal pathogen of the respiratory epithelium
- Infects virtually all children before 3 years of age
- Infection confers partial immunity → reinfection throughout life

Kliničke manifestacije RSV infekcije kod starijih

Symptoms (~5 days)

- Mild cold-like symptoms or cough
- Runny nose
- Sore throat
- Wheezing
- Headache
- Decreased appetite
- Fever - not always present
- Sputum production

Most recover within a week from RSV



*Linder et al. JAMA. 2023;330(12):1200.
Branche et al. Influenza Other Respir Viruses. 2022;16(6):1151-1160.
Talbot et al. Clin Infect Dis. 2010;50(5):747-51.
Branche et al. Drugs Aging. 2015;32(4):261-9.*

Kliničke manifestacije RSV infekcije kod starijih

Symptoms (~5 days)

- Mild cold-like symptoms or cough
- Runny nose
- Sore throat
- Wheezing
- Headache
- Decreased appetite
- Fever - not always present
- Sputum production

Most recover within a week from RSV

Complications

- Breathlessness
- Low oxygen saturation
- Pneumonia
- Can worsen respiratory disease
 - Asthma
 - COPD
 - ILD
- Functional decline if hospitalized
- Confusion, anorexia, dizziness, falls

Linder et al. JAMA. 2023;330(12):1200.


Branche et al. Influenza Other Respir Viruses. 2022;16(6):1151-1160.

Talbot et al. Clin Infect Dis. 2010;50(5):747-51.

Branche et al. Drugs Aging. 2015;32(4):261-9.


“Skriveno” opterećenje javnog zdravlja usled RSV infekcije kod starijih

The RSV burden of disease
in children aged <5 years is
well known and recorded
in >70% of cases, while
older adults have a proper
diagnosis in <10% of cases¹



RSV infekcija kod starijih i osoba pod rizikom

- US – evaluation of all respiratory illnesses in three cohorts in one hospital (Rochester, NY) during 4 consecutive winters (1999-2003)




Faktori koji dovode do neadekvatnog prepoznavanja realnog značaja RSV infekcije kod odraslih




Nedovoljno testiranje pacijenata na postojanje RSV infekcije

- SAD – 937 bolnica širom zemlje tokom tri zimske sezone (2016-2019) – osobe ≥ 65 godina hospitalizovane zbog infekcija donjeg respiratornog trakta




Neadekvatno uzorkovanje pacijenata na postojanje RSV infekcije

- US and Canada – 3669 adults aged ≥ 40 years hospitalized with ARI tested for RSV using 4 specimen types



Roughly half of RSV-positive cases were missed with NPS alone. All specimen types identified some unique positives



Adding further specimen types increased RSV detection by 112% vs. NPS alone

Starosna dob i komorbiditeti povećavaju rizik za razvoj teže forme RSV infekcije

Identified risk factors for severe RSV:^{1,3}

Older age
Chronic cardiac disease (CHF, CAD)
Chronic pulmonary disease (COPD, asthma)
Chronic kidney disease
Diabetes
Immunocompromised
Low socioeconomic status
Nursing home residence

RSV-related mortality associated with¹:

Immunocompromised status

Age >85 years

CAD – Coronary artery disease
CHF – Congestive heart failure
COPD – Chronic obstructive pulmonary disease


¹ Njue et al. *Open Forum Infect Dis* 2023;10:ofad513.

² McLaughlin et al. *Open Forum Infect Dis* 2022;9:ofac300.

³ Branche et al. *Influenza Other Respir Viruses*. 2022;16(6):1151-1160.

Uticaj starosne dobi na učestalost hospitalizacija usled RSV infekcije

- US – Adjusted RSV-associated hospitalization rates per 100,000 adults ≥ 18 years by 5-year age group and year, RSV-NET, 2015–2016 to 2019–2020



Monica Patton. Epidemiology of Respiratory Syncytial Virus Hospitalizations in Adults — RSV-NET. Advisory Committee on Immunization Practices, October 25, 2023

Uticaj komorbiditeta na učestalost hospitalizacija usled RSV infekcije

Table 3. Estimated Annual Respiratory Syncytial Virus Infection Incidence Rates per 100 000 Persons in Adults With and Without Selected Underlying Medical Conditions and Incidence Rate Ratios

Condition and Age Group	Rochester, New York			NYC		
	Incidence Rate	Incidence Rate	IRR (95% CI)	Incidence Rate	Incidence Rate	IRR (95% CI)
	With Condition	Without Condition		With Condition	Without Condition	
COPD						
18–49 y	24.87	7.83	3.18 (.99–10.17)	46.80	8.37	5.58 (1.72–18.12)
50–64 y	204.76	32.25	6.35 (2.00–20.11)	210.31	33.38	6.30 (3.75–10.58)
≥65 y	1077.36	80.32	13.41 (4.29–41.98)	529.17	150.68	3.51 (2.63–4.69)
Asthma						
18–49 y	14.72	6.11	2.41 (.74–7.86)	15.62	7.67	2.04 (1.02–4.07)
50–64 y	90.24	38.64	2.34 (.74–7.39)	110.87	30.80	3.60 (2.24–5.79)
≥65 y	261.43	103.93	2.52 (.81–7.86)	369.92	162.71	2.27 (1.67–3.09)
Diabetes						
18–49 y	65.39	5.86	11.16 (3.45–36.13)	83.39	7.29	11.43 (5.27–24.81)
50–64 y	116.77	34.79	3.36 (1.06–10.63)	113.53	31.73	3.58 (2.21–5.79)
≥65 y	501.82	77.93	6.44 (2.06–20.17)	323.08	137.65	2.35 (1.82–3.04)
Obesity						
18–49 y	8.39	6.54	1.71 (.52–5.62)	11.41	8.07	1.41 (.72–2.74)
50–64 y	53.73	36.36	2.05 (.65–6.53)	38.30	46.35	0.83 (.50–1.36)
≥65 y	167.02	89.76	3.05 (.97–9.55)	138.75	204.92	0.68 (.50–.92)
CAD						
18–49 y	50.73	7.21	7.04 (2.19–22.57)	7.80	8.96	0.87 (.12–6.33)
50–64 y	154.02	41.19	3.74 (1.19–11.78)	168.15	38.12	4.41 (2.37–8.21)
≥65 y	517.03	80.07	6.46 (2.06–20.09)	554.77	148.07	3.75 (2.82–4.98)
CHF ^a						
20–39 y	295.23	8.88	33.23 (10.14–108.90)	114.98	7.96	14.45 (1.95–107.00)
40–59 y	485.84	25.87	18.78 (5.92–59.55)	231.55	17.38	13.32 (5.94–29.89)
60–79 y	688.58	90.24	7.63 (2.43–23.93)	508.51	86.70	5.86 (4.07–8.46)
≥80 y	999.88	250.90	3.99 (1.29–12.63)	1405.15	260.38	5.40 (3.80–7.67)


Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IRR, incidence rate ratio; NYC, New York City.

Branche et al. Clin Infect Dis 2022;74:1004–11.

CAD – Coronary artery disease
CHF – Congestive heart failure
COPD – Chronic obstructive pulmonary disease
IRR – Incidence rate ration

Komplikacije i sekvele RSV infekcije kod odraslih

- RSV sequelae in adults within 1 year following RSV-related hospitalization or resolution of acute infection – A systematic review and Meta-analysis (21 studies from high-income countries 1990-2019)



Estimated relative risk of cardiovascular events in RSV vs. influenza was 1.4 (95% CI 1.0, 2.0)


Morbiditet i mortalitet RSV infekcije u odnosu na grip

- US (Northern California) – 645 RSV- and 1878 influenza-infected hospitalized adults (2011-2015)

Compared with influenza, RSV was associated with greater odds of:


- Prolonged hospital stay ($P < .001$)
- Pneumonia ($P < .001$)
- ICU admission ($P = .023$)
- COPD exacerbation ($P = .001$)
- 1-year mortality ($P = .019$)

Survival rate within 1 year of admission among patients aged ≥ 60 years hospitalized with RSV or influenza infection



Long-term survival after hospitalization was 74.2% for patients with RSV and 81.2% for patients with influenza ($p < 0.001$)

Važnost vakcinacije starijih osoba protiv RSV




Koje RSV vakcine se daju starijim osobama,
kakva je njihova efikasnost i bezbednost?

RSV vakcine odobrene za davanje starijim osobama



Bivalent stabilized
prefusion F vaccine

RSVpreF




Adjuvanted RSV prefusion F
protein-based

RSVPreF3




LNP-encapsulated mRNA-based
vaccine encoding the RSV fusion (F)
glycoprotein stabilized in the
prefusion conformation

mRNA-1345



	RSVpreF ^{1,2}	RSVpreF3 ^{3,4}	mRNA-1345 ⁵
Design	Recombinant RSVpreF A + RSVpreF B proteins (bivalent)	Recombinant RSVpreF3 A protein (monovalent)	mRNA encoding RSVpreF protein (monovalent)
Mechanism of action	Induces immune response against RSVpreF A and RSVpreF B Evidence for protection against A and B (not in label)	Induces immune response against RSVpreF3 A Evidence for cross-protection against RSV B (in label)	Induces immune response against RSVpreF Evidence for cross-protection against RSV B (not in label)
Formulation	60 µg RSVpreF A 60 µg RSVpreF B	120 µg RSVpreF3 A	50 µg of nucleoside modified mRNA encoding the RSVpreF protein
Adjuvant	Not applicable	AS01 _E adjuvant	N/A



RSV vakcine odobrene za davanje starijim osobama



Prevenција RSV infekcije kod starijih osoba vakcinacijom

AReSVi-006 Study

- International, placebo-controlled, phase 3 trial in 17 countries
- **Adults 60 years of age or older**
- A single dose of an AS01E-adjuvanted RSV prefusion F protein–based candidate vaccine (RSVPreF3)
- Entering their first RSV season
- Primary objective was to show vaccine efficacy of one dose of the RSVPreF3 vaccine against RSV-related LRTD, confirmed by RT-PCR






94.1% (95% CI, 62.4 to 99.9) against severe RSV-related LRTD
71.7% (95% CI, 56.2 to 82.3) against RSV-related ARI

Similar results for RSV A and RSV B subtypes

Prevenција RSV infekcije kod starijih osoba vakcinacijom

RENOIR Study

- Placebo-controlled, phase 3 trial in 7 countries on both hemispheres
- **Adults 60 years of age or older**
- A single intramuscular injection of bivalent RSVpreF vaccine at a dose of 120 µg (RSV subgroups A and B, 60 µg each) or placebo
- The two primary end points were vaccine efficacy against RSV-associated LRTD with either ≥ 2 signs or symptoms or ≥ 3 signs or symptoms in the first RSV season
- The secondary end point was vaccine efficacy against RSV-associated acute respiratory illness





62.1% (95% CI, 37.1 to 77.9) for against RSV-related ARI

Similar results for RSV A and RSV B subtypes

Prevenција RSV infekcije kod starijih osoba vakcinacijom

ConquerRSV Study


- Randomized, double-blind, placebo-controlled, phase 2–3 trial in 22 countries
- **Adults 60 years of age or older**
- One dose of mRNA-1345 (50 µg) or placebo
- The two primary efficacy end points were the prevention of RSV-associated LRTD with at least two signs or symptoms and with at least three signs or symptoms within 14 days to 12 months after injection
- A key secondary efficacy end point was the prevention of RSV-associated acute respiratory disease



RSV-Associated Disease with ≥ 2 Signs or Symptoms



RSV-Associated Disease with ≥ 3 Signs or Symptoms




68.4% (95% CI, 50.9 to 79.7) against RSV-associated ARI
Efficacy lower for RSV B compared to RSV A subtype

Kakva je efikasnost RSV vakcina
u sezonama koje slede nakon vakcinacije
i da li je potrebno da se daju dodatne doze?

Efikasnost RSV vakcina tokom više sezona

- Efikasnost vakcina tokom dve RSV sezone (RSVPreF3 vakcina)




Key Results

- VE over 2 seasons was **67.2%** against RSV-LRTD and **78.8%** against severe RSV-LRTD
- Revaccination 1 y post-dose 1 was well tolerated but did not seem to provide additional efficacy in the overall study population
- **Therefore, only 1 dose of RSVPreF3 OA is needed for 2 seasons in adults ≥ 60 y**
- Vaccine works in vulnerable populations and those with ≥ 1 comorbidity

Efikasnost RSV vakcina tokom više sezona


- Perzistencija tirova antitela i odgovor na revakcinaciju RSVPreF vakcinom kod odraslih



Efikasnost RSV vakcina tokom više sezona

- Efikasnost vakcina tokom dve RSV sezone (bivalentna RSVPreF vakcina)

These data are not in the SmPC. Results have been submitted for publication




CI, confidence interval; LRTI, lower respiratory tract illness; RSV, respiratory syncytial virus; RSVpreF, respiratory syncytial virus prefusion F

1. Walsh EE. Abstract P99 presented at ReSVINET; February 13-16, 2024; Mumbai, India. <https://resvinet.org/wp-content/uploads/2024/02/Scientific-Program.pdf> [Accessed July 2024];

2. Munjal I. Presentation at World Vaccine Congress; April 1-4, 2024; Washington, DC


Efikasnost RSV vakcina tokom više sezona

- Efikasnost vakcina tokom tri sukcesivne RSV sezone (RSVPreF3 vakcina)



Efikasnost RSV vakcina tokom više sezona


- Efikasnost vakcina tokom tri sukcesivne RSV sezone (mRNA-1345)



Da li su vakcine protiv RSV efiksane i bezbedne
kod imunokompromitovanih osoba
i osoba sa komorbiditetima?


Imunogenost RSV vakcina kod imunokompromitovanih osoba

- Imunogenost bivalentne RSVPreF vaccine kod odraslih imunokompromitovanih osoba



Imunogenost RSV vakcina kod imunokompromitovanih osoba



- Imunogenost bivalentne RSVPreF vaccine kod odraslih imunokompromitovanih osoba



Abbreviations: GMFR = geometric mean fold rise; GMT = geometric mean titer; NA = not applicable; RSV = respiratory syncytial virus.

Bezbednost RSV vakcina kod imunokompromitovanih osoba

- Neželjne reakcije nakon bivalentne RSVPreF vakcine kod imunokompromitovanih osoba



Prevenција RSV infekcije kod starijih osoba sa komorbiditetima



- Efikasnost RSVPreF3 vakcine kod starijih osoba sa komorbiditetima

Endpoint	RSVPreF3 OA				Placebo				Vaccine Efficacy, % (CI ^a)
	N	n	T, p-y	n/T, n/1000 p-y	N	n	T, p-y	n/T, n/1000 p-y	
RSV-LRTD									
RSV-LRTD, overall	12 466	7	6865.9	1.0	12 494	40	6857.3	5.8	82.6 (57.9–94.1)
RSV-LRTD by coexisting condition of interest ^b									
No condition of interest	7529	6	4094.1	1.5	7633	22	4148.1	5.3	72.5 (30.0–90.9)
≥1 condition of interest	4937	1	2771.8	0.4	4861	18	2709.1	6.6	94.6 (65.9–99.9)
≥1 cardiorespiratory condition of interest ^c	2496	1	1409.5	0.7	2421	12	1352.9	8.9	92.1 (46.7–99.8)
≥1 endocrine and metabolic condition of interest ^d	3200	0	1795.7	0.0	3234	13	1805.3	7.2	100 (74.0–100)
≥2 conditions of interest	2504	1	1418.2	0.7	2431	12	1362.8	8.8	92.0 (46.1–99.8)
RSV-ARI									
RSV-ARI, overall	12 466	27	6858.7	3.9	12 494	95	6837.8	13.9	71.7 (56.2–82.3)
RSV-ARI by coexisting condition of interest ^b									
No condition of interest	7529	19	4089.9	4.6	7633	54	4136.4	13.1	64.4 (39.0–80.1)
≥1 condition of interest	4937	8	2768.8	2.9	4861	41	2701.4	15.2	81.0 (58.9–92.3)
≥1 cardiorespiratory condition of interest ^c	2496	3	1408.5	2.1	2421	24	1349.0	17.8	88.1 (60.9–97.7)
≥1 endocrine and metabolic condition of interest ^d	3200	6	1793.2	3.3	3234	29	1800.0	16.1	79.4 (49.4–93.0)
≥2 conditions of interest	2504	3	1417.3	2.1	2431	24	1358.8	17.7	88.0 (60.5–97.7)

Kakva je efektivnost RSV vakcina nakon uvođenja
u programe imunizacije?


Efektivnost RSV vakcina

- SAD – elektronski registar
245 urgentnih odeljenja u 230 bolnica
(oktobar 2023-mart 2024)




Efektivnost RSV vakcina

- SAD – elektronski registar
245 urgentnih odeljenja u 230 bolnica
(oktobar 2023-mart 2024)



Imunokompromitovane osobe ≥60 godina



A kakva je bezbednost RSV vakcina nakon uvođenja
u programe imunizacije?

RSV vaccine i Guillain-Barré-ov syndrom

As of June 2024:

- ~1.3 million protein subunit RSV vaccine doses, 28 GBS cases identified through diagnostic codes
- Elevated incidence rate ratio of GBS following both GSK Arexvy and Pfizer Abrysvo vaccination, but estimates were not statistically significant
- Data suggested difference in attributable risk by product²
 - GSK Arexvy: 3 excess cases per 1 million doses (95% CI: -3, 10)
 - Pfizer Abrysvo: 16 excess cases per 1 million doses (95% CI: 3, 29)
- No data available regarding concomitant vaccinations

1. Brighton Collaboration (BC) case definition for GBS was applied, requiring Level 1–3 certainty: <https://brightoncollaboration.org/guillain-barre-and-miller-fisher-syndromes-2/>. Of the 95 initially identified cases, 51 were confirmed through medical record review, 24 were excluded (BC Level 4–5), and 20 did not have medical record available for review.
2. Residual confounding is possible, and the analysis was not designed to compare risk between the two vaccines. Baseline risk of GBS may impact estimated attributable risk.


RSV vakcine i Guillain-Barré-ov sindrom

- Procenjeni benefit vakcinacije protiv RSV tokom tri sezone u odnosu na rizik od GBS-a

Per 1 Million Persons Vaccinated with Protein Subunit RSV Vaccine:

Adults Aged ≥75 Years, General Population

Adults Aged 60–74 Years³ at Increased Risk of Severe RSV Disease



0–18⁴ attributable cases of GBS

Kakve su preporuke za davanje vakcina protiv RSV
starijim osobama u svetu?

Prevenција RSV infekcije kod starijih

- RSV vakcine su sada odobrene za korišćenje u preko 30 zemalja u svetu



Preporuke za vakcinaciju odraslih protiv RSV u svetu

- Preporuke različitih profesionalnih udruženja



Older adults

NeumoExperts Prevention (NEP) Group¹ Position Paper

NEP recommends vaccination for adults aged **≥60 years**

- **Especially those with:**

- Chronic pulmonary disease
- Chronic cardiovascular disease
- Extreme obesity
- Neurologic impairment
- Kidney disease
- Diabetes
- Immunosuppression
- Institutionalized status



Global Initiative for Chronic Obstructive Lung Disease (GOLD)² 2024 Report

The US CDC Advisory Committee on Immunization Practices and the European Commission recommend use of the available RSV vaccines for individuals aged **≥60 years**

- RSV vaccine added to recommended routine vaccination schedule list for **individuals with stable COPD**



German associations^{3,†}

RSV vaccine is recommended for:

- Adults aged **≥60 years**
- Adults of **any age with severe pulmonary or cardiovascular preexisting conditions**
- Adults of **any age with significant immune compromise**



American Diabetes Association 2024 Standards of Care in Diabetes⁴

RSV vaccines are highly recommended for older adults aged **≥ 60 years with diabetes**



Italian Board of Scientific Societies for the Vaccination Calendar for Life⁵

Recommended vaccination against RSV for:

- **All adults aged >75 years** due to the high risk of comorbidities or underlying conditions
- Adults aged **60-75 years in high-risk groups**



Preporuke za vakcinaciju odraslih protiv RSV u SAD

June 2024 ACIP Recommendations for RSV Vaccination in Older Adults:

ACIP recommends **all adults aged ≥ 75 years and adults aged 60–74 years who are at increased risk of severe RSV disease** receive a single dose of RSV vaccine.^{1,2}

1. Recommendation is for any Food and Drug Administration–approved RSV vaccine (Arexvy [GSK]; Abrysvo [Pfizer]; or mResvia [Moderna]). There is no product preference.
2. Eligible adults are currently recommended to receive a single dose of RSV vaccine; adults who have already received RSV vaccination should not receive another dose.

Britton et al. MMWR Morb Mortal Wkly Rep 2024;73:696–702.

Melgar et al. MMWR Morb Mortal Wkly Rep. 2023;72(29):793–801.

Dostupno na: https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm?s_cid=mm7332e1_w (Pristupljeno 30.10.2024.)

Preporuke za vakcinaciju odraslih protiv RSV u Evropi

Sweden

75+ All Older Adults
60+ with underlying disease
(any RSV vaccine)

Norway

60+ Older Adults with underlying disease
(any RSV vaccine)

Belgium

60+ Older Adults with underlying disease
(any RSV vaccine)

Ireland

65+ Older Adults
(any RSV vaccine)

United Kingdom

75+ Older Adults
(any RSV vaccine)

France*

60+ Older Adults with
chronic respiratory disease
(RSV PreFOA)

Poland

60+ Older Adults
(any RSV vaccine)

Germany†

75+ IC [DGHO] (any RSV vaccine)
60+ Older adults [DGP]
60+ High risk [SIKO]

Italy#

75+ All Older Adults
60+ with underlying disease
(any RSV vaccine)

Austria

60+ Older Adults
18+ High risk
(any RSV vaccine)

Israel

60+ High risk (recommended)
60+ Older Adults (shared
clinical decision making)

Spain**

60+ Older Adults
(any RSV vaccine)

■ Countries with national RSV recommendations

■ Countries with medical society/regional RSV recommendations


*Recommendation issued by OrphaLung/GREPI/SPLF/RespiFIL (French Respiratory medical societies)

† DGHO: German Society for Hematology and Oncology. DGP: German Pulmonologists Scientific Society. SIKO: Saxonian Vaccination Commission

Recommendation issued by Board del Calendario per la Vita (Calendar for Life (CPV))

**Recommendation issued by COMITÉ CIENTÍFICO SOBRE COVID-19 Y PATÓGENOS EMERGENTES DEL ICOMEM (SCIENTIFIC COMMITTEE ON COVID-19 AND EMERGING PATHOGENS OF ICOMEM) and Neumoexpertos.

Preporuke za vakcinaciju odraslih protiv RSV u svetu



*Based on shared clinical decision-making; †Can be considered at age 60–74 years in consultation with a healthcare provider; ‡CDC recommends use of the RSV vaccines in people aged 60–74 years who are at increased risk of severe RSV

CDC, Center for Disease Control and Prevention; RSV, respiratory syncytial virus; RSVpreF, respiratory syncytial virus prefusion F

1. [Impfplan Österreich](#); 2. [Vaccination schedule for the elderly - Scireptenia Info \(pzh.gov.pl\)](#); 3. Haute Autorité de Santé - Vaccine strategy for the prevention of RSV infections in adults aged 60 years and over (has-sante.fr); 4. Respiratory syncytial virus (RSV): Canadian Immunization Guide - Canada.ca; 5. [Recommendations for passive immunisation and vaccination against respiratory syncytial in infants, children and older adults](#); 6. Guidance: RSV vaccination of older adults: information for healthcare practitioners; 7. [Vaccination mot RS-virus](#); 8. CDC. CDC updates RSV vaccination recommendation for adults. June 26, 2024. <https://www.cdc.gov/media/releases/2024/s-0626-vaccination-adults.html>; 9. Australian Immunisation Handbook Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook (health.gov.au); 10. STIKO RSV Vaccination Recommendation (https://www.rki.de/DE/Content/Home/homepage_node.html); 11. Raccomandazioni del Board del Calendario per la Vita sulla vaccinazione contro Virus Respiratorio Sinciziale (VRS o RSV) nella popolazione anziana e negli adulti a rischio; 12. [RSV-vaccine - vejleder for helsepersonell](#); 13. Vaccination against RSV (adults) [all URLs Accessed August 2024]



UNIVERZITET U NOVOM SADU
MEDICINSKI FAKULTET



Nacionalni simpozijum sa međunarodnim učešćem
„4. DAN VAKCINACIJE“
6-7. novembar 2024. godine
Hotel Sheraton, Novi Sad

Hvala na pažnji!
Pitanja?



Miloš Marković
milos.markovic@med.bg.ac.rs